EKF Diagnostics Holdings
plc
("EKF",
the "Company" or the "Group")
PDMR/Director
Dealings
EKF Diagnostics Holdings
plc (AIM: EKF), the AIM-listed global
diagnostics business, announces that
the Board of EKF has been informed that on
Friday 22 March 2024, certain funds connected to Christopher Mills,
Non-Executive Director, purchased a total of 100,000 ordinary
shares of 1 pence each in the Company ("Ordinary Shares") at a
price of 25.78 pence per Ordinary Share.
Following this transaction,
Christopher Mills' total direct and indirect interest in the
Company is 132,350,000 Ordinary Shares,
representing approximately 29.169% of the total voting rights over
the Company's issued share capital.
The Notification of Dealing Form
required in accordance with UK MAR is set out below as is the
Standard form for notification of major holdings received by EKF
today.
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with
them
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Harwood Capital LLP and Harwood
Capital Management (Gibraltar) Ltd, (the "Investment
Managers")
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Christopher Mills is the
Non-Executive Director of the issuer and Chief Executive of the
Investment Managers
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
EKF Diagnostics Holdings
plc
|
|
b)
|
LEI
|
213800DXTF3EAUK1AR05
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of 1 pence
each
|
|
|
|
|
Identification code
|
GB0031509804
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
25.78p
|
100,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
N/A single transaction
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
22 March 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange,
AIMX
|
|
|
|
|
|
EKF
Diagnostics Holdings plc
|
www.ekfdiagnostics.com
|
|
Julian Baines, Executive
Chair
|
Tel:
+44 (0)29 2071
0570
|
|
|
|
|
Singer Capital Markets (Nominated
Adviser & Broker)
|
Tel: +44
(0)20 7496 3000
|
|
Aubrey Powell / Oliver
Platts
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933 8780
or ekf@walbrookpr.com
|
|
Paul McManus / Alice
Woodings
|
Mob: +44
(0)7980 541 893 / +44 (0)7407 804 654
|
|
|
|
| |
About EKF Life Sciences
EKF Life Sciences is a specialist
global manufacturer of high-quality enzymes and custom products for
use in diagnostic, pharmaceutical, and industrial
applications.
EKF Life Sciences is at the
forefront of supporting global demand in precision fermentation,
enzyme applications and research, providing innovative
biotechnology solutions to deliver advancements in healthcare and
medicine.
Utilising its unique technical
expertise, the EKF Life Sciences uses precision microbial
fermentation and advanced downstream processes to isolate and
deliver the highest quality enzymes and biomolecules that have been
specially engineered to customer specifications.
EKF Life Sciences has two
state-of-the-art GMP manufacturing facilities, located within close
proximity, in Elkhart and South Bend Indiana, one the US's major
life sciences and industrial hotspots. It operates to the highest
regulatory standards under cGMP principles, FDA certification and
ISO 13485 Quality Program. The facilities include bioreactors
ranging from 5L to 14,500L, enabling it to offer an end-to-end
service from bench/proof-of-concept through to full scale
commercial production, providing its customers with desired yields,
precision at scale and cost-efficiency.
EKF Lifesciences is also one of the
market leaders for the supply of β-HB, a reagent used to detect
ketones for patients suffering from diabetic ketoacidosis, as well
as many other clinical applications.
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global
diagnostics business focussed on:
·
Point-of-Care analysers in the
key areas of Hematology and Diabetes, as well as Central Laboratory
products including clinical chemistry reagents, analysers and
centrifuges.
· Life Sciences
services provide specialist manufacture of enzymes
and custom products for use in diagnostic, food and industrial
applications, as well as other higher value Contract Manufacturing
services.
EKF has headquarters in Penarth (near Cardiff) and operates five
manufacturing sites across the US and Germany, selling into over
120 countries world-wide.